The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy
Table 2
The four-group categorization of pathologic Gleason score 7 prostate cancer according to Gleason score upgrading after a radical prostatectomy.
Upgraded GS 3+4
Nonupgraded GS 3+4
Upgraded GS 4+3
Nonupgraded GS 4+3
p value
N
458
636
216
368
Mean age
66.7 ± 6.4
66.5 ± 6.6
66.5 ± 6.5
68.0 ± 6.2
0.003
Preoperative PSA
9.4 ± 7.6
12.6 ± 13.0
14.5 ± 26.4
15.9 ± 17.5
<0.001
Preoperative PSA level
<10
320 (69.9%)
371 (58.3%)
124 (57.4%)
179 (48.6%)
<0.001
10–20
108 (23.6%)
178 (28.0%)
53 (24.5%)
102 (27.7%)
>20
30 (6.6%)
87 (13.7%)
39 (18.1%)
87 (23.6%)
Clinical stage
T1c/T2a
411 (89.7%)
560 (88.1%)
191 (88.4%)
295 (80.2%)
0.001
T2b/c
36 (7.9%)
63 (9.9%)
18 (8.3%)
50 (13.6%)
T3-4
11 (2.4%)
13 (2.0%)
7 (3.2%)
23 (6.3%)
Pathologic finding
ECE+
134 (29.9%)
231 (36.3%)
94 (43.5%)
184 (50.0%)
<0.001
SVI+
14 (3.1%)
73 (11.5%)
27 (12.5%)
63 (17.1%)
<0.001
Surgical margin+
152 (33.2%)
264 (41.5%)
86 (39.8%)
152 (41.3%)
0.027
Biochemical recurrence
46 (10.0%)
124 (19.5%)
49 (22.7%)
105 (28.5%)
<0.001
denotes statistical significance in comparison with the other three groups; ECE: extracapsular extension; GS: Gleason score; PSA: prostate-specific antigen; SVI: seminal vesicle invasion.
